Shafaghi S, Naghashzadeh F, Sharif Kashani B, Behzadnia N, Ahmadi Z H
Lung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int J Organ Transplant Med. 2020;11(2):90-92.
Heart transplantation is the treatment of choice for those with end-stage heart failure. However, despite improvements in immunosuppressive treatment, patients are at significant risk of allograft rejection, especially early after transplantation. Any changes in patient's heart condition including reduced left ventricular ejection fraction, arrhythmia and any types of blocks need attention. Herein we report on a 29-year-old man who underwent heart transplantation 5 years before due to dilated cardiomyopathy. He was on immunosuppressive therapy and was good until one week before his admission, when he felt palpitation. Electrocardiography during palpitation showed a second-degree AV-block with heart rate of 60 beats/min. Echocardiography showed good left ventricular systolic function with no regional wall motion abnormality. The patient referred for coronary angiography and endomyocardial biopsy. The angiography was normal. The biopsy showed rejection compatible with ISHLT grade 2R. After treating the patient with 1.5 g methylprednisolone, the symptoms relieved and the block resolved. Bradycardia and second-degree AV-block late after heart transplantation could be a sign of cardiac allograft rejection and need more evaluation, especially endomyocardial biopsy.
心脏移植是终末期心力衰竭患者的首选治疗方法。然而,尽管免疫抑制治疗有所改进,但患者仍面临着显著的同种异体移植排斥风险,尤其是在移植后的早期。患者心脏状况的任何变化,包括左心室射血分数降低、心律失常和任何类型的传导阻滞都需要引起关注。在此,我们报告一名29岁男性,他因扩张型心肌病在5年前接受了心脏移植。他接受免疫抑制治疗,情况良好,直到入院前一周,他感到心悸。心悸时的心电图显示二度房室传导阻滞,心率为60次/分钟。超声心动图显示左心室收缩功能良好,无节段性室壁运动异常。该患者接受了冠状动脉造影和心内膜心肌活检。冠状动脉造影正常。活检显示排斥反应符合国际心脏和肺移植学会(ISHLT)2R级。用1.5克甲泼尼龙治疗患者后,症状缓解,传导阻滞消失。心脏移植后期出现的心动过缓和二度房室传导阻滞可能是心脏同种异体移植排斥的迹象,需要进一步评估,尤其是心内膜心肌活检。